Susanna Meyner, MSc, PhD

Global Medical Director, Neuroscience
Camurus AB, Sweden

Poster(s):

• (266) Dosing to effect with weekly and monthly subcutaneous buprenorphine: post-hoc analysis of a Phase 3, open-label study
  Wednesday, October 29, 2025